# The Big Business of Longevity Peptides, stem cells and AI: what is approved, what is only compounded, and who is actually getting paid Canonical HTML: https://www.livetradingnews.com/the-big-business-of-longevity Last modified: 2026-09-06 --- By Shayne Heffernan ยท 2026-09-06 Tags: $LLY, $NVO, $MESO, $LGVN, $BIOA, $RXRX, $BAYRY, $VRTX Signed: ML-DSA-65, anchored on Armature L1. Nothing in this article is investment advice. Longevity stopped being only a consumer-clinic story in 2024 to 2026. An MSC product is on the U.S. market. A mitochondrial peptide has an accelerated approval. Partial cellular reprogramming has been dosed in a person. A generative-AI company listed in Hong Kong and put an AI-designed fibrosis drug into Phase 3. A dog-longevity startup is two of three FDA veterinary sections from a possible first "extend healthy lifespan" label in any species. GLP-1 medicines, approved for diabetes and obesity, are the first mass-market drugs whose cardiometabolic effects look like healthspan tools even though no regulator has blessed "anti-aging" as an indication. That is the serious layer. Underneath it sits a much larger gray market of wellness peptides, "research use only" vials, and clinic stacks whose human evidence is thin. In July 2026 an FDA advisory committee voted to recommend six of those peptides for pharmacy compounding. The vote is not an approval. Agency scientists dissented. Rulemaking is unfinished. Anyone trading this field has to hold both facts at once. This is research by [Target150](https://www.target150.com/), the longevity and regenerative medicine clinic in Bangkok, built on Round Table, the proprietary ontology engine [KXCO](https://kxco.ai/) runs against private books of record. Every status, figure and company position below is held as a dated claim in a graph with its source attached, and the three charts are drawn from that graph rather than typed in by hand. The public demonstration of the engine is at [kxco.ai/ontology-live](https://kxco.ai/ontology-live/). **How to read status language here.** "FDA-approved" means a specific product and indication. "Advisory-committee recommended" is a nonbinding step toward the 503A compounding bulks list. "In the clinic" means an IND is open and people have been or will be dosed. "Wellness use" is off-label or unapproved. None of this is investment advice. ## What is actually FDA-approved A peptide is a short chain of amino acids. Insulin is a peptide. So are GLP-1 drugs. So is BPC-157, the Instagram healing peptide. Putting those in one sentence is how the category got confused. The right split is finished, reviewed medicines versus bulk substances that clinics and telehealth shops want to compound. Molecule / brand Indication that is approved Longevity relevance Semaglutide (Ozempic, Wegovy, Rybelsus) T2D, chronic weight, CV risk reduction Strongest real-world healthspan drug class of the decade. Not labeled for aging. Tirzepatide (Mounjaro, Zepbound) T2D, obesity, obstructive sleep apnea Dual GIP/GLP-1. Larger average weight loss than semaglutide in head-to-heads. Tesamorelin (Egrifta) Excess abdominal fat in HIV-associated lipodystrophy GHRH analog. Off-label visceral-fat use is common in clinics. That is not a longevity approval. Elamipretide (Forzinity, SS-31) Accelerated approval Sept 2025, muscle strength in Barth syndrome Mitochondrial cardiolipin peptide. Narrow and contingent on confirmatory work. Research vials are not Forzinity. Bremelanotide (Vyleesi, PT-141) Hypoactive sexual desire disorder Not a longevity drug. Often bundled into peptide stacks anyway. Setmelanotide (Imcivree) Rare monogenic and syndromic obesity MC4R pathway. Genetically defined, not general aging. Sermorelin (formerly Geref) Was approved for pediatric GH deficiency, withdrawn 2008 for manufacturing Still compounded. Evidence for anti-aging GH secretagogue use is limited. Sirolimus (Rapamune) Transplant immunosuppression Best-supported gerotherapeutic in animals. Human longevity use is off-label. Eight molecules carry a label. That is the whole list. ![Longevity status ladder: eight molecules carry an FDA label, six carry only a nonbinding PCAC compounding vote, ten are in the clinic and six are sold with no approval at all.](https://livetradingnews-media.nyc3.digitaloceanspaces.com/media/2026/09/06/cmpgg3-65e8afd41bc503fa.png) The distance between the top band and the second band is the commercial story of the peptide market. An approval is a named product with a named indication that survived review. A PCAC recommendation is a majority of a committee saying a compounding pharmacy should be allowed to mix the substance, in a process that still has to survive rulemaking. The gray market sells the second as though it were the first, and the fourth band as though it were the second. ## The July 2026 compounding votes On 23 and 24 July the FDA Pharmacy Compounding Advisory Committee considered seven bulk peptides for the 503A bulks list. It recommended six and rejected one. Votes were narrow, several committee members sell peptides, FDA scientists argued the human data were inadequate, and the recommendations are not binding. As of early September none of the six is lawfully on the finished 503A list because of that meeting. Peptide Use evaluated Vote What the science actually is BPC-157 Ulcerative colitis 8 to 6, recommend Gastric peptide fragment. Almost no controlled human RCTs. One tiny safety pilot. TB-500 Wound healing 8 to 6, recommend Actin-binding fragment. Human clinical literature is sparse. KPV Wounds and inflammation 8 to 6, recommend Alpha-MSH tripeptide. Mostly preclinical anti-inflammatory work. MOTS-c Obesity and osteoporosis 7 to 5, recommend Mitochondrial-encoded peptide. Promising mouse data. Human trials remain thin. Semax Cerebral ischemia, migraine recommend Russian ACTH analog used as a nootropic. Not a U.S.-approved drug. Epitalon Insomnia recommend Pineal tetrapeptide marketed for telomeres. Cancer-risk questions raised. No human aging RCTs. Emideltide / DSIP Opioid withdrawal, insomnia not recommended Delta-sleep peptide. The one no on the docket. GLP-1s and, in the right patient, tesamorelin or a prescribed GH-axis analog are medicines with labels, pharmacokinetics and known harms. BPC-157, TB-500, MOTS-c, epitalon, CJC-1295, ipamorelin and GHK-Cu sit in a different bin. Immunogenicity, peptide impurities and injection-site infection are not theoretical. A compounding-list vote does not manufacture a Phase 3 program. ## Stem cells, and the first human reprogramming dose Two different ideas travel under the words "stem cells." The first is allogeneic mesenchymal stromal cells, off-the-shelf anti-inflammatory cell products. The second is identity-preserving partial reprogramming, briefly expressing Yamanaka factors so an aged cell behaves younger without becoming a tumor risk. Only the first has an approved product. Only the second is the true make-cells-young-again bet, and it entered a person this year. Mesoblast won the first U.S. MSC approval in December 2024 with Ryoncil for steroid-refractory acute graft-versus-host disease. 2026 filings describe launch revenue on the order of a hundred million dollars and a pipeline pushing the same platform into adult GvHD, Duchenne muscular dystrophy, Revascor for ischemic heart failure, and a fully enrolled 350-patient Phase 3 in chronic low-back pain, treated out in August with the primary readout later. Longeveron is the listed company that most explicitly labels an aging indication. Laromestrocel is in four programs: hypoplastic left heart syndrome with ELPIS II top-line targeted this quarter, mild Alzheimer's on RMAT and Fast Track, pediatric dilated cardiomyopathy, and aging-related frailty. A Phase 2b frailty analysis in Cell Stem Cell reported a 63-meter gain in six-minute walk distance at nine months against placebo. That is a functional aging endpoint, not a lifespan claim. The company is small and financing-constrained. The science is more interesting than the balance sheet. In June, Nature reported that a participant had received a cellular-reprogramming gene therapy aimed at making damaged eye cells younger. That is Life Biosciences' ER-100, an AAV-delivered OSK construct for glaucoma and non-arteritic anterior ischemic optic neuropathy. FDA allowed the Phase 1 to proceed and Life raised an $80 million Series D to fund it. It is the first regulated human test of partial reprogramming. It is local, eye-limited and safety-first, with years of follow-up because gene therapies persist. It is not a systemic youth shot. ## The money, and what it has put into a person Funding figures disagree across trackers because they mix founder pledges, extensions and rumored second closes. Treat the order of magnitude as the fact. Reprogramming absorbed the majority of hard-science longevity capital and has produced one Phase 1 eye study and one autophagy Phase 1. That ratio is the central risk of the sector. ![Disclosed private longevity capital against programmes with an open IND. Altos Labs has the biggest war chest and nothing in a person. Life Biosciences has the least cash and the only human dose.](https://livetradingnews-media.nyc3.digitaloceanspaces.com/media/2026/09/06/cmpgg3-4c36b852c84a5bb6.png) Read the right-hand column first. Altos Labs has the largest disclosed war chest in the field and no programme in a person. NewLimit has raised close to a billion dollars and has told the market 2027. Life Biosciences has the smallest balance sheet of the four reprogramming names and is the only one whose therapy has been administered to a human being. Capital and regulatory progress are not the same axis, and in this sector they are close to uncorrelated. The chart shows disclosed capital. Calico and Rubedo are drawn as not disclosed rather than as zero, because an absent figure and a figure of nothing are different facts. ## The listed names that matter Most listed longevity tickers are tiny. The economic center of healthspan in 2026 is still two metabolic giants and a handful of platform or cell-therapy names. Company Ticker What it owns in this story Eli Lilly $LLY Tirzepatide franchise, retatrutide in late development, the $2.75bn Insilico AI deal signed in March, and NewLimit via Lilly Ventures. Novo Nordisk $NVO Semaglutide franchise, oral and next-gen incretins, MASH and CV labels that look like healthspan even when the word is never used. Insilico Medicine 3696.HK Generative-AI discovery platform, rentosertib in Phase 3, a 2026 deal stack with Lilly, Servier, Takeda and SK Bio, and the first profitable half after its HKEX listing. Mesoblast $MESO The only FDA-approved MSC. Trying to industrialize the platform into heart failure, back pain and DMD. Longeveron $LGVN MSC frailty, Alzheimer's and HLHS. Highest aging labeling among microcaps. Binary on 2026 and 2027 readouts. BioAge Labs $BIOA Human-longevity-data platform, BGE-102 against NLRP3, Novartis and Lilly discovery pacts, and the azelaprag scar tissue. Recursion $RXRX Phenomic maps and partnered programmes. Aging is a use case, not the mission. Bayer / BlueRock $BAYRY iPSC Parkinson's Phase 3. Cell replacement at pharma scale. Vertex $VRTX Islet cell therapy for type 1 diabetes. Aging-relevant as proof that replacement biology can be commercial. Unity Biotechnology is absent because it is gone. UBX0101 failed in osteoarthritic knees, UBX1325 did not beat aflibercept on its pre-specified non-inferiority clock, and the company cut staff in May 2025, delisted, and dissolved that September. The lesson is not that senolytics are dead. It is that clearing senescent cells in a structurally ruined tissue is not the same as restoring function, and public-market timelines punish that gap. Liquidity and dilution risk in the microcaps above are not theoretical. ## Ranked by evidence, not marketing ### Already changing population health Semaglutide and tirzepatide reduce weight, blood pressure, liver fat, sleep apnea, kidney events and major adverse cardiac events in large outcomes trials. That is not a mouse lifespan paper, it is millions of patients. Next-wave triple agonists and oral incretins will decide whether the class becomes a durable healthspan standard or a weight-loss boom that fades when lean mass and GI dropout dominate. SGLT2 inhibitors belong on the same shelf: approved for diseases, used as healthspan tools by thoughtful clinicians. ### Approved molecules, unapproved aging claims Rapamycin is still the cleanest lifespan result in mammals when you average the Interventions Testing Program, but PEARL was muddied by compounding bioavailability problems and nobody has a labeled human longevity dose. Metformin has cheap multi-hallmark pharmacology and a composite-endpoint trial the FDA was willing to entertain, and that trial has spent years waiting for money. Elamipretide is the only new peptide approval longevity Twitter immediately claimed, and its label is Barth syndrome muscle strength on a surrogate. ### Mechanisms that could still matter Oral NLRP3 inhibition becomes the first purpose-built geroscience small molecule with a commercial disease path if BioAge's Phase 2 data hold. Rubedo's skin-lesion readout is the first post-Unity human senolytic hint that looks like a product. Partial reprogramming has the highest ceiling and the highest catastrophic-failure mode. ### Popular, not proven NAD precursors have human biomarker papers, no mortality data and quality-control chaos. BPC-157, TB-500, epitalon and MOTS-c as anti-aging therapy are mechanism posters, not Phase 3. Young plasma and exosome drips are legally and scientifically fraught. Telomerase activators are still a cancer-risk conversation pretending to be a protocol. ## What AI actually does, and who leads AI does not solve aging. It compresses four bottlenecks: nominating targets from human aging data, generating chemistry against those targets, searching reprogramming cocktails combinatorially rather than by a scientist's favorite three genes, and reading trial endpoints off second-generation epigenetic clocks instead of waiting twenty years. What it does not do is invent a regulatorily acceptable aging indication, replace toxicology, make a 503A peptide safe, or excuse a company that has $3bn and no IND. Independent multi-model scorecards published this year put Insilico first with unusual agreement. That kind of meta-ranking is marketing-adjacent. The more useful exercise is to score the field on three things a reader can check: who has a late-stage molecule, who pharma will write nine-figure cheques to, and who can repeat the trick. ![AI longevity companies scored on three checkable tests: a Phase 3 asset, deals with a published figure, and named pharma counterparties. Insilico Medicine is the only name passing all three.](https://livetradingnews-media.nyc3.digitaloceanspaces.com/media/2026/09/06/cmpgg3-e5b0028fa52d2596.png) Insilico listed on the Hong Kong Main Board in December 2025, cleared a profit test rather than a pre-revenue biotech chapter, and reported first-half 2026 revenue around $106 million and its first profitable half as a public company. Its own September disclosure puts 2026 announced contract value near $7.3bn. The bar above sums only the three deals carrying a published figure, $6.1bn, so the gap is the Takeda pact and the China partnerships, which carry no number. The honest reading is narrower than the headline. Insilico is ahead on the industrial version of the question, and that lead rests on one Phase 3 asset in one indication in one country. Rentosertib is at the stage where most drugs fail. Isomorphic Labs is infrastructure the rest of the field depends on and is not competing for the longevity label. The reprogramming names have the highest ceiling and the least to show a regulator. ## What Target150 and KXCO are building Everything above is a survey of other people's evidence. Readers are entitled to know who is holding the pen. Target150 is a longevity and regenerative medicine clinic at 622 Emporium Tower, Sukhumvit 24, Bangkok. It administers stem cell therapy, NK cell therapy, AFS cells, peptide protocols and bio-longevity screening, and its clients travel from Australia, the United Kingdom, the United States, Europe and the Middle East. Its mission is to extend mental and physical longevity for as long as possible, keeping people sharp, strong and well across every decade of life. That is a healthspan goal, not a number. KXCO built and hosts the clinic's technical infrastructure and owns Round Table, the ontology engine this article was researched on. What is live today is unglamorous and it is the point. The clinical record carries protocols with cell source, passage number and batch on every administered item, because a protocol without provenance of what was administered cannot be reviewed later. Laboratory panels carry the document identifier and a content hash of the report they were read off, so a reader can check the report has not changed underneath them. Symptoms record who reported them, separating what the patient said from what a clinician observed. Round Table carries a clinical-longevity category of 15 object types and 21 link types. What it deliberately does not carry is the more interesting half. No reference ranges, because ranges differ by laboratory and assay and a stored range would be a clinical opinion with no author. No optimal or target values, because the field disagrees and a target belongs to a named practitioner. No biological age and no pace-of-ageing composite, because nothing in the model computes a number from other numbers. No intervention effects, because populating them from the literature would turn a medical record into a recommendation engine. Every one of those absences is a decision. The evidence corpus loaded against that vocabulary holds 25 studies, 29 interventions, 30 markers and 53 intervention-to-marker effect links. Twenty-two of those 53 links record a null result or a harm, and one is animal-only and flagged as such. A corpus that only kept the wins would be a brochure. Target150 and KXCO are building a patient-facing AI advisor on top of that record. The design is fixed: it reads the patient's own profile, active protocol and latest laboratory results through the ontology, so every answer is grounded in that patient's record rather than in a general model's impression of longevity medicine. It is not built. Five commercial decisions remain open, covering what it is called, how access is metered, how permissive it should be on grey-zone health questions, whether physician notes sit inside its context, and how it is priced. It is named here as work under way, not as a shipped product. ## How to watch the next 24 months - Longeveron ELPIS II top-line in hypoplastic left heart syndrome, targeted this quarter. Pediatric heart surgery is not aging, but a BLA path would refinance the frailty and Alzheimer's story. - BioAge QUELL-CV Phase 2 in the second half. Does an oral NLRP3 inhibitor look like a cardiometabolic drug? - Insilico rentosertib Phase 3 enrollment quality in China, and whether a U.S. or global path is disclosed. - Life Biosciences ER-100 safety, slow by design. A clean year of ocular gene-therapy follow-up is the reprogramming industry's permission structure. - Loyal's manufacturing section for LOY-002. If CVM signs the last page, the first official longevity drug may be beef-flavored. - Mesoblast chronic low-back-pain Phase 3 primary, mid-2027 on current company language, and any heart-failure filing strategy update. - FDA final action, if any, on the six recommended peptides. Until a Federal Register rule lands, the July votes are theater plus optionality. - TAME funding. If metformin's aging trial never starts, the claim that the FDA accepted aging as an endpoint stays historical. - NewLimit's IND. 2027 is the date they have sold. Slippage would be informative. ## The sober close In 2026 the honest hierarchy is metabolic drugs that already exist, cell products that treat inflammation and injury, one mitochondrial peptide with a rare-disease label, a veterinary program that may legalize lifespan as a word, and a reprogramming-and-AI stack that has more money than human outcomes. That hierarchy will flip if ER-100 is safe and functional, if a senolytic finally wins a hard endpoint, or if an AI-designed geroscience drug does what rentosertib is trying to do in fibrosis. Until then the most evidence-based longevity protocol is still unglamorous: ApoB, blood pressure, fitness, muscle, sleep, tobacco, and when indicated an incretin or an SGLT2. Everything else is a clinical trial, a compounding experiment, or a press release. Know which one you are holding. Stocks mentioned in this article: $LLY, $NVO, $MESO, $LGVN, $BIOA, $RXRX, $BAYRY and $VRTX. Shayne Heffernan, Ph.D., is the founder of Live Trading News, the KnightsBridge Group, Knightsbridge Law and the KXCO.ai ecosystem spanning post-quantum cryptography, identity, attestation and enterprise ontology. Not medical advice, not a recommendation to buy or sell any security, and not an endorsement of compounded or research-only peptides. Indications, tickers, trial timings and deal values change. Check primary FDA, SEC and HKEX filings before acting. --- This Markdown mirrors https://www.livetradingnews.com/the-big-business-of-longevity. The HTML page is canonical. Site index for AI clients: https://www.livetradingnews.com/llms.txt